MedTrace Logo

Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

NCT02337985 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-11-10

No results posted yet for this study

Summary

This pilot clinical trial studies gene therapy following combination chemotherapy in treating patients with acquired immune deficiency syndrome (AIDS)-related non-Hodgkin lymphoma. Placing genes that have been shown in the laboratory to inhibit the growth and spread of the immunodeficiency virus (HIV) into the patient's peripheral blood stem cells may improve the body's ability to fight HIV. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving gene therapy after combination chemotherapy may improve the body's ability to fight HIV and AIDS-related non-Hodgkin lymphoma.

Conditions

  • AIDS-Related Burkitt Lymphoma
  • AIDS-Related Diffuse Large B-cell Lymphoma
  • AIDS-Related Plasmablastic Lymphoma
  • AIDS-Related Primary Effusion Lymphoma
  • HIV Infection
  • AIDS Related Non-Hodgkin Lymphoma

Interventions

DRUG

Prednisone

Given PO

BIOLOGICAL

Rituximab

Given IV

DRUG

Etoposide

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Vincristine Sulfate

Given IV

DRUG

Cyclophosphamide

Given IV

BIOLOGICAL

Filgrastim

Given SC

BIOLOGICAL

Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Amrita Krishnan, MD · City of Hope Medical Center

  • Mark J. Roschewski, MD · NCI Lymphoid Malignancy Branch

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-20
Primary Completion
2026-09-08
Completion
2026-09-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02337985 on ClinicalTrials.gov